Skip to main content

Table 1 Demographic, clinical characteristics, demographic, and medications

From: Sex differences in soluble prorenin receptor in patients with type 2 diabetes

Variables Total participants Men Women
Control Type 2 diabetes Control Type 2 diabetes Control Type 2 diabetes
Participants, n (%) 173 (64) 96 (36) 71 (63) 41 (37) 102 (65) 55 (35)
Age 39 (13) 55 (9) 40 (13) 56 (8) 39 (13) 55 (10)
Caucasians, n (%) 114 (42) 44 (16) 44 (16) 19 (7) 70 (26) 25 (9)
African American, n (%) 59 (22) 52 (20) 27 (55) 22 (45) 32 (51) 30 (49)
Clinical analysis       
 BMI (kg/m2) 28 (7.9) 37.5 (7.4) 28 (6.9) 38 (7) 28 (8.6) 37 (7.8)
 WHR 0.8 (0.1) 0.9 (0.1) 0.91 (0.08) 1.0 (0.05) 0.81 (0.07) 0.89 (0.1)
 SBP (mm Hg) 118 (15) 132 (22) 121(14) 133 (25) 116 (15) 131 (20)
 DBP (mm Hg) 74 (11) 80 (12) 74 (12) 80 (14) 73 (12) 80 (12)
 Fasting glucose (mg/dL) 77 (19) 134 (54) 82 (18) 150 (54) 75 (19) 122 (51)
 HbA1C (%) 7.6 (1.7) 8.3 (2) 7.2 (1)
 Serum creatinine (mg/dL) 0.85 (0.1) 1.2 (1.9) 0.98 (0.15) 1.67 (2.9) 0.75 (0.1) 0.83 (0.2)
 ACR (mg albumin/gCr) 28 (26) 76 (79) 27 (29) 78 (77) 29 (23) 74 (82)
 uCreatinine (mg/L) 0.7 (0.4) 0.5 (0.2) 0.7 (0.4) 0.6 (0.2) 0.7 (0.4) 0.5 (0.2)
 eGFR (mL/min per 1.73 m2) 95 (21) 83 (26) 94 (17) 77 (28) 95 (23) 87 (24)
Medications       
 No meds, n (%) 169 (63) 25 (9) 69 (62) 10 (9) 99 (63) 15 (9)
 ARB, n (%) 13 (5) 5 (5) 8 (5)
 ACEi, n (%) 2 (1) 30 (11) 2 (2) 12 (10) 3 (2) 18 (11)
 ARB/ACEi, n (%) 4 (1) 3 (3) 1 (1)
 β-adrenergic blockers, n (%) 2 (1) 19 (7) 11 (10) 8 (5)
 Calcium channel blockers, n (%) 1 (1) 1 (1)
 Diuretics, n (%) 4 (2) 4 (3)
 Diabetes medication, n (%) 1 (0.4) 80 (30) 1 (1) 35 (32) 46 (29)
  1. Data are expressed as mean (SD). ARB angiotensin-II type 1 receptor blocker, ACEi angiotensin-converting I enzyme inhibitors. Anti-diabetic medications include insulin, metformin, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonist, sulfonylureas, and thiazolidinediones